WegovyClinical review16:07

STEP-1 trial results explained: what 15% really means

Channel: Clinical Trials Today • Published November 12, 2024

Note: This YouTube ID is a placeholder pending real-video curation. The page surface and schema are live; the embed will render once a real ID is published.

Clinical breakdown of the STEP-1 trial that supported Wegovy approval — what the 15% mean weight loss represents and what it does not.

Key takeaways

STEP-1: 68 weeks, n=1961, 15% mean weight loss vs 2.4% placebo
One-third of completers lost ≥20% body weight
Discontinuation rate ~7% for GI adverse events
Cardiometabolic markers (HbA1c, BP, lipids) improved across the cohort

Editorial transcript

Paraphrased editorial summary by the GLP1Zoom team — not a verbatim transcript of the video.

[Editorial transcript pending — to be filled by content team. Until then this placeholder ships so the page structure + schema + URL surface are all live and crawlable; the editorial team will replace this body before public link-out.]

Our take

The cleanest layperson-grade walkthrough of the STEP-1 dataset we have seen.

About this transcript

GLP1Zoom does not produce video content. We curate publicly available YouTube videos and write our own editorial summaries — paraphrased and factual, never verbatim. The video itself remains the property of its creator and is embedded via YouTube's privacy-enhanced no-cookie domain. This page is not sponsored. Read our editorial policy →